INTRODUCTION
The increasing incidence 1 and earlier diagnosis of papi llary thyroid cancer (PTC) have prompted a search for prognostic indicators apart from the traditional histo logical correlates of aggressiveness. Advances in ultrasonographic screening and aspiration biopsy allow clinicians to detect concerning nodules earlier, including micro PTC. Given the very favorable prognosis of PTC overall, difficulties arise in distinguishing which micro PTC require aggressive treatment and which do not. 2, 3 To that end, much current research effort focuses on accurate and reliable markers for aggressive behavior in such lesions. Traditionally, there are four pathological features for aggressive behavior in PTC. Capsular invasion (CI) is tumor growth through the lymph node capsule. 4 A potentially more ominous second criterion is extrathy roidal extension (ETE) of the primary tumor into the surrounding tissues. Multiple foci of vascular invasion are also a feature of aggression. Regional lymph node metastasis (LNM) is a sign of agg ressive behavior in patients over 45 years of age. Each of these features may require additional treatment, such as more extensive sur gery (e.g. functional neck dissection) or radioactive iodine. BRAF is a serine/threonine kinase and a part of the mitogen activated protein kinase/extracellular signal related kinase (MAPK/ERK) signaling pathway. This pathway plays a role regulation of cell cycle, differen tiation and lysosomal processing. 5 Commonly muta tions of BRaf protooncogene (BRAF) occur at exon 15, which leads to constitutive activation and subsequent onco genesis. 6 The most common mutation is a tyrosine to adenine switch at base 1799, which changes that reading frame to produce a glutamic acid residue at position 600 rather than a valine residue (V600E). Research has shown this mutation plays a critical role in melanoma, 7 colorectal 8 and thyroid cancers. In mice, the V600E mutation can lead to more tumorassociated macrophages as well as epithelial to mesenchymal transition, allowing increased migration, and thus a higher likelihood of invasion or metastasis. 9 In the thyroid, researchers have shown that 18 Kim et al studied 547
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PTC of all sizes and found the BRAF mutation in 64% of samples with ETE. 19 Howell et al, in 2011, looked at 219
PTCs ranging from 0.2 to 5 cm, 20 finding 39% of these samples contained the BRAF mutation, and 77% with ETE contained BRAF mutation. An updated metaanalysis by Kim selected 27 studies including 5655 patients and concluded that PTC patients with the BRAF (V600E) mutation had increased odds ratios of extrathyroidal invasion, lymph node metastasis and an advanced TNM stage. 21 According to National Cancer Institute Surveillance, Epidemiology and End Results (NCISEER) statistics, patients with PTC with LNM, ETE, or vascular inva sion have a 10 years survival rate between 91 and 94% (Graph 1). While this may seem high, it is much lower than the 98.4% relative survival rate of all PTC patients or the 99.6% 10 years survival rate of PTC patients without any of the aggressive features. In lieu of detailed followup data from patients in this study, these three pathological features can be used as a surrogate for poor prognosis.
The goal of this study was to further characterize the role of BRAF V660E in classically aggressive pathologic features compared to other nonaggressive tumors, and determine whether testing for this mutation should be used as a prognostic indicator in surgical and therapeutic decisions.
MATERIALS AND METHODS
This protocol was reviewed and approved by our institu tional IRB. Sixtysix thyroid samples were collected and were cut into 20 µm sections and the deoxyribonucleic acid (DNA) was extracted using the chemagic magnetic separation module extraction robot (Chemagen). DNA was quantified using the NanoDrop 2000. BRAF muta tion status was analyzed by realtime PCR using castPCR BRAF assays (Life Technologies). V600E mutant and wild type BRAF mutation assays were used for each sample. Twenty ng of DNA was used for each assay. Internal positive controls were also added to each assay, using exogenous DNA and a different fluorescent dye. Statistical testing was done using the Fisher exact test to determine a correlation between V600E BRAF mutation and the aggre ssive features. Samples were divided into 'aggressive' or 'nonaggressive' groups. Forty-five of the 66 samples were labeled aggressive by meeting at least one of the four features of ETE, LNM, CI, or vascular invasion; the remaining 21 were labeled nonaggressive.
RESULTS
BRAF mutation positivity was found in 27 of the 45 aggre ssive samples (60.0%). Five of 21 nonaggressive samples were positive for the BRAF mutation (23.8%). Using the Fisher exact test, a significant correlation was demonstrated between these aggressive features and the BRAF mutation with a pvalue less than 0.007. Individually, only LNM and ETE were significantly correlated with the mutation. Over 75% of the samples with extrathy roidal extension were found to carry the BRAF mutation (p = 0.0022), and over 65% of the samples with lymph node metastasis carried the mutation (p = 0.0067). Vascular invasion and ECE were not significantly correlated with the mutation. This is summarized in Graph 2.
To determine if the patient's age at diagnosis had an effect on BRAF mutation, the samples were also separated into groups based on being over or under 60 years of age (the median age of patients was 52.5 ± 14). There was no correlation between patient age and BRAF mutation status based on this age criterion.
Because, this study focused on fresh, frozen samples, there was little clinical followup data. In lieu of that data, Graph 1: NCI-SEER survival data for pathological features of clinical aggressiveness. LMN, ETE, and vascular invasion all show poor prognosis with relative survival falling below 95% over 10 years samples that had any of the three pathological features (lymph node metastasis, extrathyroidal extension, vascu lar invasion) with relative survival rates less than 95% were categorized as having poor prognosis. Nonaggressive samples and those displaying only capsular invasion and nonaggressive samples were categorized as having a good prognosis. When categorized like this, the V600E BRAF mutation is significantly correlated with poor prog nosis with a pvalue less than 0.002 (Graph 3). However, there was only 60% sensitivity and 80% specificity of the assay to prognosis, making BRAF a poor singular marker for prognosis based on pathological aggressive features.
DISCUSSION
While the overriding feature of PTC is a benign prog nosis, aggressive features, such as ETE, LNM, CI and vascular invasion may predict higher rates of recurrence or mortality. Testing for BRAF mutation may offer a mole cular modality for the guidance of treatment in higher risk patients. The goal of this study was to determine if BRAF mutation testing can be used to predict any or all of the aggressive features for PTC. Detection of BRAF V600E mutation in all samples from this series was (48.5%) agrees with majority of previous reports, falling in the 45 to 55% range.
Extrathyroidal extent is likely the most important of the aggressive features and the second most common (seer database). In the cohort for this study, 21 out of the 45 aggressive samples exhibited ETE. This result corrobo rates work done by Howell et al. 19, 20, 2224 The MAPK/ERK pathway regulates cell division. A mutation, like V600E, activating this pathway would cause unchecked growth, causing the cancer to extend to the surrounding tissue. Lymph note metastasis is the most common of the aggre ssive features (SEER) and was also found to corre late with the V600E BRAF mutation in our study. This was the most common of the four pathological features, with 32 of the 45 aggressive patients containing this factor as well as the most common of the four pathological features according to the SEER statistics. Lymph note meta stasis will prompt a regional neck dissection and may also require postoperative radioactive iodine ablation. Whether the BRAF mutation can predict which levels of the neck would be involved with metastases could be studied further.
With the two most common pathological aggressive features significantly correlated to the BRAF muta tion, it follows that the samples displaying any of the four features were also found to be significantly correlated to the mutation. The correlation of LNM and ETE with the V600E BRAF mutation concurs with the metaanalysis aggregated by Kim. 19 Vascular invasion and CI were not significantly correlated with BRAF in our study. While having the worst survival rate over 10 years, vascular invasion is the least common of the four pathological features for aggressiveness accor ding to SEER. In the cohort for this study, however, 21 of the 45 samples exhibited vascular invasion. The mutation testing showed sensitivity to vascular inva sion to be less than 60%. Capsular invasion was the least common in this cohort of samples and had the highest survival rate over 10 years according to the SEER data. According to SEER data from 1998 to 2008, patients with capsular invasion in PTC had a relative survival rate of 98.5%. Because of this survival rate, which is higher than the 10year survival rate of all PTC patients in the SEER database between 1998 and 2008, this aggressive criterion was not used as a measure of poor prognosis. 
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Advanced age at time of diagnosis also affects prog nosis of the patient. Surveillance, epidemiology and end result data show that patients over 60 at time of diagnosis have a drop in survival after the 8th year, and this drops the rate below the rate of overall PTC. Results show that BRAF mutation does not correlate with samples over 60 years of age at time of diagnosis. Therefore, the BRAF mutation testing is not hindered by age effects as an early marker for clinical aggressiveness.
This suggests that the MAPK signaling pathway is also being activated either upstream or downstream from BRAF. One cause of upstream activation may be the wellknown ret proto oncogene/papillary thyroid cancer (RET/PTC) translocation, while activation of NFK maybe activated by other means downstream of BRAF. These other activating mechanisms of MAPK pathway are currently being studied and further examination is warranted.
CONCLUSION
The V600E BRAF mutation is correlated with samples having one or more of the four classic features for aggre ssiveness. This is primarily driven by the mutation corre lating with the two most common of these features, extrathyroidal extension and lymph node metastasis. When these features are used as a surrogate gauge for patient prognosis, the mutation test is shown to be unsuit able as a lone early marker for aggressiveness. With only 60% sensitivity and 80% specificity of the assay to poor prognosis based on three of the pathological features, the BRAF mutation test would overlook too many patients to be used as a lone marker for early aggressiveness.
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